The University of Texas System

Immune-onc Therapeutics, Inc.

Xun Gui

Zhiqiang An

Ningyan Zhang

Chengcheng Zhang

Mi Deng

Wei Xiong

Qiang Liu

X Charlene Liao

Junke Zheng

Tao Huang

Jaehyup Kim

Jingjing Xie

The present disclosure provides an isolated monoclonal antibody or an antigen-binding fragment thereof that binds specifically to leukocyte immunoglobulin-like receptor 4 (LILRB4). In certain embodiments, the antibody or antigen-binding fragment, when bound to LILRB4, modulates the activation of LILRB4. In certain embodiments, the antibody or antigen-binding fragment, when bound to LILRB4, activates LILRB4. In certain embodiments, the antibody or antigen binding fragment, when bound to LILRB4, suppresses activation of LILRB4. In certain embodiments, the antibody or antigen-binding fragment, when bound to LILRB4, specifically blocks binding of ApoE to LILRB4. In another aspect, there is provided a method of treating or ameliorating the effects of a cancer in a subject, comprising administering to the subject a therapeutically effective amount of the antibody or an antigen-binding fragment thereof or an engineered cell as provided herein.

LILRB4 antibodies and uses thereof

Provided herein are methods and compositions for the identification of modulators of ApoE-induced LILRB activation. Also provided herein are methods of treating cancer comprising the administration of an inhibitor of ApoE-induced LILRB activation. Also provided are methods of treating autoimmune disease or inhibiting the onset of transplant rejection or treating an inflammatory disorder comprising administering an agonist of ApoE-induced LILRB activation to a subject.

Methods for identifying LILRB-blocking antibodies

The present disclosure is directed to antibodies binding to LILRBs and methods of detecting and treating cancer therewith.

Anti-LILRB antibodies and their use in detecting and treating cancer

The present disclosure is directed to antibodies binding to LAIR 1 and their treating cancer, inflammation, immune-related diseases or transplantation.

Anti-leukocyte-associated immunoglobulin-like receptor 1 (LAIR1) monoclonal antibodies and method of use thereof to treat cancer

Growing community of inventors

Houston, TX, United States of America

Xun Gui